



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11/2645
#9
Bp
6-15-02

Attorney Docket No.: DEX-0214

Inventors: Macina et al.

Serial No.: 09/909,567

Filing Date: 20 July 2001

Examiner: Unknown


Group Art Unit: 1645

Title: Compositions and Methods Relating
to Lung Specific Genes

RECEIVED
JUN 05 2002
TECH CENTER 1600/2900

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: May 29, 2002


Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above



identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application. No additional fee is required.

RECEIVED

JUN 05 2002

TECH CENTER 1600/2900

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

- () A copy of the of the PCT Search Report for PCT Application @@ which corresponds to the subject US application @@ is included.

- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark



Office in prior application Serial No. _____, filed
, for which a claim for priority under 35 U.S.C. §120
has been made in the instant application.

(XX) Due to the large size of some references, only
relevant portions have been submitted. The included
portions are as follows: EP 1066182 A2 (Pages 1-383,
503, 602-609); WO 00/58473 A2 (pages 1-92, 101, 360,
410-421, 4781-4784, 5503-5507); WO 01/34627 A1 (pages
1-412, sequence listing pages 1, 18-20, 54-56); WO
01/36432 A2 (pages 1-398, sequence listing 1, 5-6, 18-
19); WO 01/53312 A1 (pages 1-142, 271, 289, 604-607,
sequence listing 1, 3094-3099, 7353-7355). Full text
of abbreviated reference is available if requested.

(XX) Reference WO 01/87956 A1 is in a foreign language.
Therefore, a Geneseq Search report is attached to
demonstrate relevance.

Please charge any deficiency or credit any overpayment to
Deposit Account No. 50-0434. This form is submitted in
duplicate.


Respectfully submitted,

Nathan P. Letts

Registration No. 36,581

Date: May 29, 2002

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400



Identifier: ABA05172 cDNA Sequence 1844 BP
Release Info: Derwent Geneseq Database Release No. 200210; Date released 05-MAY-02
Database XReference: WPI; 2002-055692/07.;P-PSDB; AAM47363.
Accession Number: ABA05172
Patent Title: ATP-dependent helicase 50 and encoding polynucleotide, used in diagnosis and treatment of malignant tumors, hemopathy, human immunodeficiency virus infection, immunological diseases and inflammation -
Patented by: (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
Inventor: Mao Y, Xie Y
Description: Human DEAE and DEAH box family ATP-dependent helicase 50 cDNA
Patent Number: WO200187956-A1
Patent Publication Date: 22-NOV-2001
Modification Date: 04-MAR-2002 (first entry)
Local Filing: 14-MAY-2001; 2001WO-CN00785
Priority: 19-MAY-2000
Abstract: The present invention provides the protein and coding sequences of human DEAE and DEAH box family ATP-dependent helicase 50. The sequences can be used in the treatment of cancer, haemopathy, HIV infection, immune diseases and inflammation. The present sequence is the coding sequence of the invention.
KeyWords: Human;DEAE and DEAH box family ATP-dependent helicase 50;cancer;haemopathy;HIV infection;immune disease;inflammation;cytostatic;haemostatic;virucide;immunomodulatory;antiinflammatory;gene therapy;ss.
Organism: Homo sapiens.
Sequence Composition: Sequence 1844 BP; 533 A; 389 C; 426 G; 496 T; 0 other;
Sequence: >ABA05172 WO200187956-A1 PA (BIOW-) BIOWINDOW PR 19-MAY-2000 PF 14-MAY-2001 Human DEAE and DEAH box family ATP-dependent helicase 50 cDNA. [Homo sapiens.]
GACACACAAGATGGCGGCACCCGAGGAACACGATTCTCCGACCGAAGCGTCCCAGCCGAT
TGTGGAAGAGGAGGAACTAAAACATTTAAAGACCTGGGTGTGACAGATGTGTTGTGTGA
AGCTTGTGACCAGTTGGGATGGACAAAACCCACCAAGATTCAGATTGAAGCTATTCCTTT
GGCCTTACAAGGTCGTGATATCATTGGGCTTGCAAGAACTGGCTCTGGAAAGACAGGCGC
CTTTGCTTTGCCATTCTAAACGCACTGCTGGAGACCCCGCAGCGTTTGTGTTGCCCTAGT
TCTTACCCCGACTCGGGAGCTGGCCTTTCAGATCTCAGAGCAGTTTGAAGCCCTGGGGTC
CTCTATTGGAGTGCAGAGTGCTGTGATTGTAGGTGGAATTGATTCAATGTCTCAATCTTT
GGCCCTTGCAAAAAAACCATATAATAATAGCAACTCCTGGTCGACTGATTGACCACTT
GGAAAAATACGAAAGGTTTCAACTTGAGAGCTCTCAAATACTTGGTCATGGATGAAGCCGA
CCGAATACTGAATATGGATTTTGGAGACAGAGGTTGACAAGATCCTCAAAGTGATTCTCG
AGATCGGAAACATTCCTCTTCTCTGCCACCATGACCAAGAAGGTTCAAAAACCTTCAGCG
AGCAGCTCTGAAGAATCCTGTGAAATGTGCCGTTTCTCTAAATACCAGACAGTTGAAAA
ATTACAGCAATATTATATTTTTATTCCCTCTAAATTCAAGGATACCTACCTGGTTTATAT
TCTAAATGAATTGGCTGGAACTCCTTTATGATATTCTGCAGCACCTGTAATAATACCCA
GAGAACAGCTTTGCTACTGCGAAATCTTGGCTTCACTGCCATCCCCCTCCATGGACAAAT
GAGTCAGAGTAAGCGCCTAGGATCCCTTAATAAGTTTAAGGCCAAGGCCCGTTCCATTCT
TCTAGCAACTGACGTTGCCAGCCGAGGTTTGACATACCTCATGTAGATGTGGTTGTCAA
CTTTGACATTCTACCCATTCCAAGGATTACATTCATCGAGTAGGTGCAACAGCAGTAGAGC
TGGGCGCTCCGGAAAGGCTATTACTTTTGTACACAGTATGATGTGGAACCTTTCCAGCG
CATAGAACTTAATTGGGAAGAACTACCAGGTTTCCAACACAGGATGATGAGGTTAT

RECEIVED

JUN 03 2002

TECH CENTER 1600/2900



GATGCTGACAGAACGCGTCGCTGAAGCCCAAAGGTTTGCCCGAATGGAGTTAAGGGAGCA
TGGAGAAAAGAAGAAACGCTCGCGAGAGGATGCTGGAGATAATGATGACACAGAGGGTGC
TATTGGTGTGAGGAACAAGGTGGCTGGAGGAAAAATGAAGAAGCGGAAAGGCCGTTAATC
ACTTTTATGAAGGCTCGAGTTCTGCTGTTCTGTAAAAGAGAATTGGAGAATGAAACCTGC
TCCAACAGAGATCATGAGACTGAAATTGGTCAGAATTGTGTCCAGAATGTGCTCAGCTAA
TTCAGTATTCTTCCCCATTCTGGGTTGGAGTTTACTGCAGAGTAATTCTTACAGTGCTGA
TGTCAAGACTGTTACTGTTCTTCGACTTTGATTCTTGCTCATGACATGAGTAGGGTGTG
CTCTTCTGTCACTTCACACAGACCTTTTGCCTTTTTAGCTGCAAGTCAAGGACTAGGTT
GATGATGCCCATGACCTGTAATTGTAAAGAAGCTTGGACATCTGCAAATGATATTTAAAC
CATCTTGGCTTGTGCTTATTCAAATAATGTGAAACAATAAATTTAAATATTATTTTA
AAAGACAAAAAAAAAAAAACATGTCGGCCGCCTCGGGCCTATG

Identifier: ABA05177 DNA Sequence 41 BP
Release Info: Derwent Geneseq Database Release No. 200210; Date released 05-MAY-02
Database XReference: WPI; 2002-055692/07.
Accession Number: ABA05177
Patent Title: ATP-dependent helicase 50 and encoding polynucleotide, used in diagnosis and treatment of malignant tumors, hemopathy, human immunodeficiency virus infection, immunological diseases and inflammation -
Patented by: (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
Inventor: Mao Y, Xie Y
Description: DEAE and DEAH box family ATP-dependent helicase 50 cDNA probe #1.
Patent Number: WO200187956-A1
Patent Publication Date: 22-NOV-2001
Modification Date: 04-MAR-2002 (first entry)
Local Filing: 14-MAY-2001; 2001WO-CN00785
Priority: 19-MAY-2000
Abstract: The present invention provides the protein and coding sequences of human DEAE and DEAH box family ATP-dependent helicase 50. The sequences can be used in the treatment of cancer, haemopathy, HIV infection, immune diseases and inflammation. The present sequence is a probe for the coding sequence of the invention.
KeyWords: Human;DEAE and DEAH box family ATP-dependent helicase 50;cancer;haemopathy;HIV infection;immune disease;inflammation;cytostatic;haemostatic;virucide;immunomodulatory;antiinflammatory;gene therapy;probe;ss.
Organism: Homo sapiens.
Sequence Composition: Sequence 41 BP; 9 A; 15 C; 12 G; 5 T; 0 other;
Sequence: >ABA05177 WO200187956-A1 PA (BIOW-) BIOWINDOW PR 19-MAY-2000 PF 14-MAY-2001 DEAE and DEAH box family ATP-dependent helicase 50 cDNA probe #1. [Homo sapiens.] TGGCGGCACCCGAGGAACACGATTCTCCGACCGAAGCGTCC

Identifier: ABA05178 DNA Sequence 41 BP
Release Info: Derwent Geneseq Database Release No. 200210; Date released 05-MAY-02

Database
XReference: WPI; 2002-055692/07.

Accession
Number: ABA05178

Patent Title: ATP-dependent helicase 50 and encoding polynucleotide, used in diagnosis and treatment of malignant tumors, hemopathy, human immunodeficiency virus infection, immunological diseases and inflammation -

Patented by: (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.

Inventor: Mao Y, Xie Y

Description: DEAE and DEAH box family ATP-dependent helicase 50 cDNA probe #2.

Patent
Number: WO200187956-A1

Patent
Publication
Date: 22-NOV-2001

Modification
Date: 04-MAR-2002 (first entry)

Local Filing: 14-MAY-2001; 2001WO-CN00785

Priority: 19-MAY-2000

Abstract: The present invention provides the protein and coding sequences of human DEAE and DEAH box family ATP-dependent helicase 50. The sequences can be used in the treatment of cancer, haemopathy, HIV infection, immune diseases and inflammation. The present sequence is a probe for the coding sequence of the invention.

KeyWords: Human;DEAE and DEAH box family ATP-dependent helicase 50;cancer;haemopathy;HIV infection;immune disease;inflammation;cytostatic;haemostatic;virucide;immunomodulatory;antiinflammatory;gene therapy;probe;ss.

Organism: Homo sapiens.

Sequence
Composition: Sequence 41 BP; 9 A; 16 C; 11 G; 5 T; 0 other;

Sequence: >ABA05178 WO200187956-A1 PA (BIOW-) BIOWINDOW PR 19-MAY-2000 PF 14-MAY-2001 DEAE and DEAH box family ATP-dependent helicase 50 cDNA probe #2. [Homo sapiens.] TGGCGGCACCCGAGGAACACCATTCTCCGACCGAAGCGTCC



RECEIVED

JUN 05 2002

TECH CENTER 1600/2000